AIM ImmunoTech Inc (NYSE American:AIM)
| 0.4214 Delayed Data As of Mar 24 |  -0.0184 / -4.18%Today’s Change | 0.29 Today|||52-Week Range 1.38 | +35.11% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $22.6M |
Company Description
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Contact Information
AIM ImmunoTech, Inc. 2117 SW Highway 484 Ocala Florida 34473 |
Employees
Shareholders
| Mutual fund holders | 5.68% |
| Other institutional | 5.47% |
| Individual stakeholders | 2.00% |
Top Executives
| Thomas Kenwood Equels | Executive Vice Chairman, President & CEO |
| Peter W. Rodino | COO, Secretary & General Counsel |
| Robert Dickey | Chief Financial Officer |
| David R. Strayer | Chief Medical Officer |
| Christopher McAleer | Chief Scientific Officer |
